Poster

A Pre-Post Evaluation of Healthcare Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population

Commonwealth Medicine is now ForHealth Consulting at UMass Chan Medical School. More information available here. This content has not been updated with the new name.

Eliza Anderson, PharmD
Karen Stevens, PharmD Clinical Consultant Pharmacist, Clinical Pharmacy Services
Rachel Bacon, PharmD
Stephanie Tran, PharmD, BCPS
Caroline Alper, MD
Thomas Pomfret, PharmD, MPH, BCPS Clinical Consultant Pharmacist Team Lead and Residency Program Director, Clinical Pharmacy Services
Karen Clements, ScD Senior Project Director, Research and Evaluation
Pavel Lavitas, PharmD, BCPS Clinical Team Lead, Clinical Pharmacy Services
Kimberly Lenz, PharmD, MBA, FAMCP Senior Pharmacy Director, MassHealth/Office of Clinical Affairs

Asthma is a common disease-state that has a high societal cost, especially in the treatment of severe asthma. This research evaluated whether the initiation of dupilumab, a biologic indicated for asthma, reduced asthma-related emergency department visits or hospitalizations, the number of asthma rescue medications used, and the total cost of asthma-related exacerbations among MassHealth members. The data showed a reduction in emergency department visits and hospitalizations as well as the number of asthma rescue medications used; however, these findings were not statistically significant.

A Pre-Post Evaluation of Health Care Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Populat